Coherus Biosciences Accounts Payable

Coherus Biosciences posts a accounts payable of $13M as of June 2026. That compares with $38M in the prior-year period — down 65.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Coherus Biosciences's accounts payable was $38M. The latest reading is $13M — a 65.0% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Accounts Payable is one piece of Coherus Biosciences's financial statement story. At $13M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for CHRS's accounts payable usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Coherus Biosciences's other metric pages and overview cover the third.

Judging Coherus Biosciences against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in accounts payable easier to interpret. Start with $13M here, then scan peer and history charts to see if the gap is persistent.